As part of the Israel Trade Commission’s series on Israel’s Breakthrough Innovations, we are pleased to invite you to hear from Yossi Ben-Yossef, CEO and Founder of Kadimastem. Kadimastem is an innovative and exciting Israeli biotechnology company focused on the industrial development and commercialization of human pluripotent stem cell (hPSC)-based therapeutic solutions for Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS).
Yossi will be speaking on the topic:
“Breakthrough methods for developing human stem cell based drugs and treatment”
Date: Monday 14th October
Time: 11am – 12:00 pm
Venue: Investec, Level 23, Chifley Tower, 2 Chifley Square, Sydney
RSVP: Please confirm your attendance by replying to this email. Places are complimentary but strictly limited.
About the Speaker
Mr. Ben-Yossef co-founded Kadimastem in 2009, along with Prof. Michel Revel. Prior to Kadimastem, he has been leading investments and taking an active role in successful Biotech/Life Sciences companies in the last 12 years. Among the companies he was involved with are Evogen (TASE: EVGN), Rosetta Genomics (NASDAQ:ROSG), and Biondvax TASE: BNDX.
To schedule a private meeting with Mr Ben-Yossef please contact the Israel Trade Commission on (02) 9388 0382